Paralysis News and Research

RSS

Paralysis is the loss of muscle function in part of your body. It happens when something goes wrong with the way messages pass between your brain and muscles. Paralysis can be complete or partial. It can occur on one or both sides of your body. It can also occur in just one area, or it can be widespread. Paralysis of the lower half of your body, including both legs, is called paraplegia. Paralysis of the arms and legs is quadriplegia.

FDA stops operations of N.Y.-based beverage company

At the request of the U.S. Food and Drug Administration, the U.S. Department of Justice today filed a complaint for permanent injunction against a Jamaica, N.Y.-based beverage company to prevent it from processing and distributing juice and other products.

14 Jan 2011

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer caused by human papillomavirus (HPV) types 16 and 18 and for the prevention of anal intraepithelial neoplasia (AIN) grades 1, 2 and 3 (anal dysplasias and precancerous lesions) caused by HPV types 6, 11, 16 and 18, in males and females 9 through 26 years of age.

23 Dec 2010

Spinal Botox injection reduces pain

Botulinum neurotoxin type A (BoNT/A)—better known as Botox—reduces responses to an inflammation-related pain stimulus when injected into the spinal canal in mice, reports a study in the January issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

22 Dec 2010

Exciting progress made in MS research during 2010

Exciting advances were made in 2010 in virtually every field of MS research. Progress toward finding new therapies for MS is illustrated by the availability of the first oral disease-modifying therapy for MS. Progress was also made toward finding ways to restore function and improving quality of life and specific MS symptoms through exercise, meditation, rehabilitation and medications, including the first therapy specifically approved to treat a symptom of MS (Ampyra).

20 Dec 2010

31-year-old mother with Gorham-Stout syndrome goes home with virtually rebuilt spine

Laurie Harms, Los Angeles, feared she'd never hold her infant daughter, Sky, again. A devastating and extremely rare bone-eroding disease - Gorham-Stout syndrome - had left the 31-year-old crumpled in a hospital bed - her neck broken, arms limp and useless, and voice muted by tubes.

10 Dec 2010

News outlets report on polio outbreaks in Central, East Africa

"Bad immunisation strategy has been blamed for an outbreak of polio, which has killed nearly 200 and is believed to have caused paralysis in more than 2,000 others across Angola, Congo and the Democratic Republic of the Congo," the Mail & Guardian writes in a story examining the emergence of the disease in the three countries and efforts to control it.

10 Dec 2010

Microsurgical technique effective in removing acoustic tumors

Surgery to remove tumors under the brain known as acoustic neuromas produces favorable outcomes in the "vast majority" of patients, according to one of the largest studies of its kind.

8 Dec 2010

Swissmedic authorizes Phase I/II clinical trial of human neural stem cells for chronic spinal cord injury

A therapy developed by Aileen Anderson and Brian Cummings of UC Irvine's Sue and Bill Gross Stem Cell Research Center in collaboration with researchers at StemCells Inc. will be the basis of the world's first clinical trial using human neural stem cells to treat spinal cord injury.

8 Dec 2010

StemCells receives Swissmedic authorization to initiate HuCNS-SC Phase I/II clinical trial in spinal cord injury

StemCells, Inc. announced today that is has received authorization from Swissmedic, the Swiss regulatory agency for therapeutic products, to initiate a Phase I/II clinical trial in Switzerland of the Company's proprietary HuCNS-SC® product candidate (purified human neural stem cells) in chronic spinal cord injury. The trial is designed to assess both safety and preliminary efficacy in patients with varying degrees of paralysis who are three to 12 months post-injury, and will progressively enroll patients based upon the severity of injury.

7 Dec 2010

Tips for avoiding, treating snakebites

Should you be the victim of a snakebite, the best thing you can do is get to a hospital as quickly as possible, according to a new review article from the Journal of the American Academy of Orthopaedic Surgeons (JAAOS). Current medical treatments, including new medications and surgery, if necessary, are far more effective for snakebites than anything you can do on your own.

2 Dec 2010

Cytheris' combinational therapy demonstrates possible therapeutic strategy for PML

Cytheris SA, a clinical-stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the publication of a case study report based on successful treatment of Progressive Multifocal Leukoencephalopathy (PML) with combination therapy consisting of two investigational agents, Cytheris' recombinant human interleukin-7 (CYT107) and CMX001, an investigational, oral broad-spectrum antiviral drug (Chimerix, Research Triangle Park, NC) in the Journal of Antimicrobial Chemotherapy.

30 Nov 2010

Plant-derived bioscavenger protects against pesticide and nerve agent organophosphate poisoning

The brain is forever chattering to itself, via electrical impulses sent along its hard-wired neuronal "Ethernet." These e-messages are translated into chemical transmissions, allowing communication across the narrow cleft separating one neuron from another or between neurons and their target cells. Of the many kinds of molecules involved in this lively chemical symposium, acetylcholine is among the most critical, performing a host of functions in the central and peripheral nervous system.

24 Nov 2010

Researchers find link between acrolein and multiple sclerosis

Researchers have found evidence that an environmental pollutant may play an important role in causing multiple sclerosis and that a hypertension drug might be used to treat the disease.

24 Nov 2010

Study estimates cost savings associated with global polio eradication; global post examines vaccination efforts in Africa

Research published in the November issue of the journal Vaccine found that a global campaign to eliminate polio could save between $40 billion and $50 billion over the next few decades if the crippling disease is wiped out within five years Bloomberg reports.

24 Nov 2010

NC family hopes to win Pepsi Refresh Project grant to fund research for Alternating Hemiplegia of Childhood

A Rolesville, NC family is hoping to win the Pepsi Refresh Project that could help to find a cure for a rare neurological disorder for which there is no current cure. Matthew Wuchich, age 3, was diagnosed with Alternating Hemiplegia of Childhood or AHC when he was 18 months old. Winning the grant is important to the family and to others with the disease since rare diseases often are overlooked by more common ailments.

23 Nov 2010

Global initiative to eradicate polio could provide benefits of at least US$40-50 billion

A new study released today estimates that the global initiative to eradicate polio could provide net benefits of at least US$40-50 billion if transmission of wild polioviruses is interrupted within the next five years. The study provides the first rigorous evaluation of the benefits and costs of the Global Polio Eradication Initiative (GPEI)--the single largest project ever undertaken by the global health community. The study comes at a crucial time--following an outbreak in the Republic of the Congo and one in Tajikistan earlier this year--that highlight the risk of delays in finishing the job on polio.

23 Nov 2010

New editorial dispel doubts about Lou Gehrig's ALS diagnosis

A recent study suggesting that amyotrophic lateral sclerosis (ALS) may be attributed to repetitive head trauma experienced in collision sports lacks scientific epidemiological evidence to support this claim.

20 Nov 2010

New findings show promising treatment for MS

Successfully treating and reversing the effects of multiple sclerosis, or MS, may one day be possible using a drug originally developed to treat chronic pain, according to Distinguished Professor Linda Watkins of the University of Colorado at Boulder.

19 Nov 2010

Spleen cells may do more harm than good at site of spinal cord injury

The spleen, an organ that helps the body fight infections, might also be a source of the cells that end up doing more harm than good at the site of a spinal cord injury, new research suggests.

18 Nov 2010

Multiple sclerosis drug shows promise to counteract effects of botulinum neurotoxin

Scientists are reporting that variants of a drug already approved for treating multiple sclerosis show promise as a long sought treatment for victims of bioterrorist attack with botulinum neurotoxin which is 10,000 times deadlier than cyanide and the most poisonous substance known to man.

18 Nov 2010

Paralysis News and Research

Further Reading

FDA stops operations of N.Y.-based beverage company

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Spinal Botox injection reduces pain

Exciting progress made in MS research during 2010

31-year-old mother with Gorham-Stout syndrome goes home with virtually rebuilt spine

News outlets report on polio outbreaks in Central, East Africa

Microsurgical technique effective in removing acoustic tumors

Swissmedic authorizes Phase I/II clinical trial of human neural stem cells for chronic spinal cord injury

StemCells receives Swissmedic authorization to initiate HuCNS-SC Phase I/II clinical trial in spinal cord injury

Tips for avoiding, treating snakebites

Cytheris' combinational therapy demonstrates possible therapeutic strategy for PML

Plant-derived bioscavenger protects against pesticide and nerve agent organophosphate poisoning

Researchers find link between acrolein and multiple sclerosis

Study estimates cost savings associated with global polio eradication; global post examines vaccination efforts in Africa

NC family hopes to win Pepsi Refresh Project grant to fund research for Alternating Hemiplegia of Childhood

Global initiative to eradicate polio could provide benefits of at least US$40-50 billion

New editorial dispel doubts about Lou Gehrig's ALS diagnosis

New findings show promising treatment for MS

Spleen cells may do more harm than good at site of spinal cord injury

Multiple sclerosis drug shows promise to counteract effects of botulinum neurotoxin

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News